These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8187299)

  • 1. Persistent elevation of serum oestradiol levels by functional ovarian cysts despite effective pituitary desensitization with GnRH agonists.
    Jenkins JM; Anthony FW; Lee A; Masson GM; Thomas E
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):357-9. PubMed ID: 8187299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation.
    Lindner C; Braendle W; Lichtenberg V; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):132-9. PubMed ID: 2139863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
    Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
    Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR.
    Broekmans FJ; Bernardus RE; Broeders A; Berkhout G; Schoemaker J
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):579-87. PubMed ID: 8334744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of buserelin in an IVF programme for pituitary-ovarian suppression prior to ovarian stimulation with exogenous gonadotrophins.
    Ibrahim ZH; Matson PL; Buck P; Critchlow JD; Newman MC; Horne G; Hughes S; Lieberman BA
    Hum Reprod; 1990 Apr; 5(3):258-62. PubMed ID: 2112554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a sustained release formulation of the gonadotrophin-releasing hormone agonist histrelin on serum concentrations of gonadotrophins and oestradiol, and ovarian LH/human chorionic gonadotrophin receptor content in the rat.
    Gunnet JW; Demarest KT; Hahn DW; Ericson E; McGuire JL
    J Endocrinol; 1991 Nov; 131(2):211-8. PubMed ID: 1744568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation by oestradiol of serum levels of LH and FSH and pituitary levels of gonadotrophin-releasing hormone receptors after ovariectomy in the rat.
    Rosen H; Jameel ML; Dee C; Barkan AL
    J Endocrinol; 1989 Nov; 123(2):249-56. PubMed ID: 2558145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone.
    Develioglu OH; Cox B; Toner JP; Oehninger S; Muasher SJ
    Hum Reprod; 1999 May; 14(5):1168-74. PubMed ID: 10325255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous evaluation of basal FSH and oestradiol response to GnRH analogue (F-G-test) allows effective drug regimen selection for IVF.
    Ranieri DM; Phophong P; Khadum I; Meo F; Davis C; Serhal P
    Hum Reprod; 2001 Apr; 16(4):673-5. PubMed ID: 11278216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of functional ovarian cysts during pituitary down-regulation.
    Jenkins JM; Anthony FW; Wood P; Rushen D; Masson GM; Thomas E
    Hum Reprod; 1993 Oct; 8(10):1623-7. PubMed ID: 8300817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment.
    Engmann L; Sladkevicius P; Agrawal R; Bekir JS; Campbell S; Tan SL
    Fertil Steril; 1999 Jan; 71(1):22-9. PubMed ID: 9935111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GnRH challenge test: a quantitative measure of pituitary desensitization during GnRH agonist administration.
    Scheele F; Hompes PG; Lambalk CB; Schoute E; Broekmans FJ; Schoemaker J
    Clin Endocrinol (Oxf); 1996 May; 44(5):581-6. PubMed ID: 8762735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives.
    van Heusden AM; Coelingh Bennink HJ; Fauser BC
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):509-17. PubMed ID: 11966744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.